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Nuclear egress of TDP-43 and FUS 
occurs independently of Exportin-1/
CRM1
Helena Ederle1,2, Christina Funk3,4, Claudia Abou-Ajram1, Saskia Hutten1, Eva B. E. Funk5, 
Ralph H. Kehlenbach6, Susanne M. Bailer3,4 & Dorothee Dormann  1,2,7
TDP-43 and FUS are nuclear proteins with multiple functions in mRNA processing. They play key 
roles in ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia), where they are 
partially lost from the nucleus and aggregate in the cytoplasm of neurons and glial cells. Defects in 
nucleocytoplasmic transport contribute to this pathology, hence nuclear import of both proteins 
has been studied in detail. However, their nuclear export routes remain poorly characterized and it 
is unclear whether aberrant nuclear export contributes to TDP-43 or FUS pathology. Here we show 
that predicted nuclear export signals in TDP-43 and FUS are non-functional and that both proteins are 
exported independently of the export receptor CRM1/Exportin-1. Silencing of Exportin-5 or the mRNA 
export factor Aly/REF, as well as mutations that abrogate RNA-binding do not impair export of TDP-43 
and FUS. However, artificially enlarging TDP-43 or FUS impairs their nuclear egress, suggesting that 
they could leave the nucleus by passive diffusion. Finally, we found that inhibition of transcription 
causes accelerated nuclear egress of TDP-43, suggesting that newly synthesized RNA retains TDP-43 in 
the nucleus, limiting its egress into the cytoplasm. Our findings implicate reduced nuclear retention as a 
possible factor contributing to mislocalization of TDP-43 in ALS/FTD.
The RNA-binding proteins TDP-43 (TAR DNA-binding protein of 43 kDa) and FUS (Fused in sarcoma) have 
become infamous over the past years as being the main culprits in two fatal neurodegenerative diseases, ALS 
(amyotrophic lateral sclerosis) and FTD (frontotemporal dementia). ALS is characterized by a progressive degen-
eration of motor neurons, which causes muscle weakness and eventually complete muscle paralysis. ALS patients 
typically die due to respiratory failure, usually 3–5 years after disease onset1. In FTD, a progressive degeneration 
of the frontal and temporal cortex leads to behavioral or language dysfunction. Eventually patients show severe 
cognitive impairment and die typically 7–10 years after disease onset2. ALS and FTD belong to the same dis-
ease spectrum and are thought to have a similar molecular cause, namely mislocalization and aggregation of 
RNA-binding proteins and, consequently, defective mRNA processing3.
TDP-43 and FUS are ubiquitously expressed proteins that belong to the family of heterogenous nuclear rib-
onucleoproteins (hnRNPs). Their main site of localization is the nucleus, where they bind to gene promotors 
or long introns of pre-mRNAs and regulate transcription or splicing, respectively3–7. They also play a role in 
miRNA biogenesis and are associated with lncRNAs in paraspeckles7–9. A small fraction of TDP-43 and FUS 
is found in the cytoplasm, where they regulate stability, transport and translation of certain mRNA targets10–12. 
In post-mortem brains of ALS and FTD patients, however, the localization of TDP-43 or, less frequently, FUS is 
dramatically altered: TDP-43 or FUS are lost from the nucleus of many neurons and glial cells and accumulate in 
large cytoplasmic protein aggregates, also called inclusions13–15. Occasionally, cells that have lost TDP-43 or FUS 
from the nucleoplasm also show intranuclear TDP-43 or FUS inclusions15,16, although this is much more rarely 
seen than cytoplasmic TDP-43 or FUS inclusions. On a functional level, this is thought to cause a loss of their 
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normal mRNA processing functions. Moreover, TDP-43 or FUS aggregates are thought to gain novel toxic func-
tions, e.g. due to aberrant protein/RNA interactions or altered mRNP granule dynamics12,17.
Research over the past few years has provided strong evidence that nuclear import defects contribute to the 
nuclear loss and cytoplasmic accumulation of TDP-43 and FUS and to ALS and FTD pathogenesis18–20. First, 
genetic mutations that alter or truncate the nuclear localization signal (NLS) of FUS and thus cause impaired 
nuclear import of FUS, cause familial ALS21–24 or motor neuron degeneration in mice25–27. Second, FTD patients 
with TDP-43 aggregates were shown to have reduced cortical levels of Exportin-2 (CAS)28. This Exportin 
re-exports the nuclear import receptor Importin α into the cytoplasm and therefore is required for proper 
Importin α/β-dependent nuclear import29. TDP-43 is imported into the nucleus by Importin α/β28,30, hence 
reduced Exportin-2 levels impair its nuclear import28. Third, the most common genetic cause of familial ALS and 
FTD, a hexanucleotide (GGGGCC) repeat expansion in the C9orf72 gene, is thought to functionally compromise 
the nuclear transport machinery, as several components involved in protein import, protein export as well as 
mRNA export are strong genetic modifiers of C9orf72 repeat-associated toxicity31–35. Consequently, enhancing 
nuclear import of TDP-43 and FUS could be a promising therapeutic approach, but will most likely be very hard 
to implement.
An alternative therapeutic approach could be to curb nuclear export of TDP-43 and FUS, in order to com-
pensate for poor nuclear import and to restore normal nuclear TDP-43 and FUS levels. Inhibition of nuclear 
export as a therapeutic strategy has already been tested in preclinical models of C9orf72- and TDP-43-associated 
ALS and FTD: Here, specific inhibitors of the nuclear export receptor CRM1 (Exportin-1), KPT-276 and 
KPT-335, alleviated C9orf72 repeat-mediated neurodegeneration in the drosophila eye33 and reduced TDP-43 
overexpression-induced cell death in cortical neurons36, respectively. In another study, the CRM1 inhibitors 
KPT-276 and KPT-350 were shown to protect against axonal damage in preclinical models of demyelination and 
glutamate-induced neurotoxicity37, although the underlying mechanisms are not well understood.
CRM1 exports nuclear proteins that contain a so-called leucine-rich nuclear export signal (NES), which con-
tains four closely spaced hydrophobic residues (Φ) and follows the consensus sequence Φx2–3Φx2–3ΦxΦ38,39. In the 
presence of RanGTP in the nucleus, CRM1 directly binds such NESs with its cargo binding site and transports the 
NES-containing cargo across nuclear pore complexes (NPCs) into the cytoplasm40,41. Here, RanGAP promotes 
conversion of RanGTP into RanGDP, which leads to dissociation of the CRM1-cargo complex. Whether CRM1 
also recognizes TDP-43 and FUS and mediates active nuclear export of the two proteins is unknown. So far, a 
CRM1-dependent NES has been predicted in the RRM2 domain of TDP-43 and mutation of key hydrophobic 
residues were shown to result in nuclear aggregation of TDP-4330. A leucine-rich NES has also been predicted in 
the RRM domain of FUS23,42 and deletion of this putative NES was shown to suppress toxicity associated with NLS 
mutant versions of FUS43. Despite these interesting observations, functionality of the predicted NESs has not been 
tested in bona fide nuclear export assays.
In this study we used the interspecies heterokaryon assay as a nuclear export assay to address whether pre-
dicted CRM1-dependent NESs in TDP-43 and FUS are functional and whether pharmacological inhibition or 
silencing of CRM1 blocks nuclear export of TDP-43 and FUS. As our results demonstrate CRM1-independent 
nuclear egress of TDP-43 and FUS, we addressed whether RNA-binding, the mRNA export machinery or the 
export receptor Exportin-5 are required for nuclear export of TDP-43 or FUS. As this was not the case, we engi-
neered enlarged versions of TDP-43 and FUS to test whether nuclear egress of TDP-43 and FUS occurs by passive 
diffusion rather than active receptor-mediated export. Finally, using biochemical extraction and fluorescence 
loss in photobleaching (FLIP) experiments, we obtained support for the hypothesis that newly synthesized RNA 
anchors TDP-43 in the nucleus and limits its egress into the cytoplasm. Our results raise the possibility that tran-
scriptional inhibition or defective RNA-binding may accelerate diffusion of TDP-43 out of the nucleus and thus 
may contribute to cytoplasmic mislocalization of TDP-43 in ALS and FTD patients.
Results
Predicted CRM1-dependent NESs in TDP-43 and FUS are not functional. Using bioinformatic 
NES prediction tools (NES finder 0.2 and NetNES 1.1 Server), we identified two putative CRM1-dependent 
NESs in each TDP-43 (at positions 222 and 239) and FUS (at positions 289 and 301) (Fig. 1A). NES-239 
(IAQSLCGEDLII) in TDP-43 and NES-289 (VQGLGENVTI) in FUS have been previously predicted as CRM1-
dependent NESs23,30, however their activity has not been verified in bona fide nuclear export assays. NES-222 
(IPKPFRAFAF) in TDP-43 and NES-301 (VADYFKQIGI) in FUS, which also fulfill the consensus criteria for 
recognition by CRM1, have not been predicted and studied before. To address the functionality of these predicted 
NESs, we introduced mutations that should abrogate CRM1-binding, by exchanging two key hydrophobic resi-
dues of one or both predicted NESs for alanine (A) (Fig. S1A). When expressed in HeLa cells, all mutant proteins 
showed the same cellular localization as wild-type (WT) TDP-43 and FUS (Fig. S1B). We then examined nuclear 
export of WT and NES-mutant versions (mNES) of TDP-43 and FUS in the interspecies heterokaryon assay, a 
well-established nuclear export assay44. In this assay, cells from two different species (e.g. human and mouse) 
are chemically fused to generate hybrid cells, so-called interspecies heterokaryons (see schematic diagram in 
Fig. S2A). If the nuclear protein-of-interest shuttles between the nucleus and cytoplasm, it will enter the other 
nucleus and accumulate there over time. The assay is carried out in the presence of a protein synthesis inhibitor 
to exclude that the signal in the receptor nucleus comes from newly synthesized protein in the cytoplasm. We 
expressed V5-tagged TDP-43 or HA-tagged FUS (WT or NES-mutant versions) in human HeLa cells and fused 
them with mouse embryonic fibroblasts to examine whether shuttling from the human to the mouse nucleus 
occurred in interspecies heterokaryons. TDP-43 accumulated in mouse nuclei (marked by an asterisk) over the 
course of 2 hours, whereas FUS shuttled at a slightly slower rate and prominently appeared in mouse nuclei after 
5 hours (Fig. S2B). Similar to the WT proteins, both single and double NES mutants of TDP-43 and FUS accu-
mulated in mouse nuclei 2–5 hours post-fusion, whereas the non-shuttling control protein hnRNP-C was only 
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detectable in human nuclei (Fig. 1B). Thus, the predicted NESs in TDP-43 and FUS do not appear to be required 
for nuclear export of TDP-43 and FUS. To substantiate this finding, we introduced the double NES mutation 
into TDP-43 and FUS constructs carrying a mutated nuclear localization signal (mNLS). These mutant proteins 
Figure 1. Predicted NESs of TDP-43 and FUS are non-functional. (A) Schematic diagrams of TDP-43 and 
FUS. TDP-43 contains an internal classical bipartite nuclear localization signal (cNLS), whereas FUS contains 
a proline-tyrosine (PY)-NLS at the C-terminus (in red). For each protein, two putative CRM1-dependent NESs 
(in green, key hydrophobic amino acids underlined) were predicted using bioinformatic NES prediction tools. 
They are localized within RNA-recognition motif (RRM) domains of TDP-43 and FUS. (B) Heterokaryon assay 
performed to analyze nuclear export of TDP-43 and FUS. HeLa cells expressing the indicated V5-tagged TDP-
43 or HA-tagged FUS constructs were fused with mouse embryonic fibroblasts and the resulting heterokaryons 
were incubated for 2 h (TDP-43) and 5 h (FUS), respectively, in the presence of cycloheximide. Cells were 
stained with a V5- or HA-specific antibody (green), a human hnRNP-C-specific antibody to visualize a non-
shuttling control protein in human nuclei (magenta) and DAPI as a nucleic acid stain (blue). The appearance 
of TDP-43 and FUS in the murine nucleus (marked with an asterisk in the DAPI channel) indicates that both 
proteins undergo nuclear export, in contrast to the non-shuttling control protein hnRNP-C. Mutation of key 
hydrophobic amino acids in one or both predicted NESs (mNES or double mNES) does not abrogate nuclear 
export, demonstrating that the predicted NESs are not necessary for TDP-43 or FUS export. Scale bars: 20 μm. 
(C) HeLa cells were transiently transfected with V5-tagged TDP-43 or HA-tagged FUS constructs carrying a 
mutated NLS (mNLS) or both a mutated NLS and mutations in the predicted NESs (mNLS-double mNES). 
Cells were stained with a V5- or HA-specific antibody (green) and DAPI (blue) and localization of mutant 
proteins was examined by fluorescence microscopy. Scale bars: 20 μm.
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show impaired nuclear import and hence a partial cytosolic mislocalization45. We reasoned that if one of the two 
predicted NESs would be functional, mutating them should shift the equilibrium towards a more nuclear localiza-
tion. However, the double NES mutation did not alter the nucleocytoplasmic localization of NLS mutant TDP-43 
and FUS (Fig. 1C). To further address functionality of the predicted NESs, we fused them to the C-terminus of 
EGFP, which is localized in both the nucleus and the cytoplasm, with a predominant nuclear localization46. We 
reasoned that if the predicted NESs would be functional, the fusion proteins should be recognized by CRM1 and 
actively exported to the cytoplasm. However, none of the EGFP-NES fusion proteins showed a more cytoplasmic 
localization when compared to EGFP alone (Fig. S2C). Together, our data demonstrate that TDP-43 and FUS can 
leave the nucleus, but that the predicted CRM1-dependent NESs are neither necessary nor sufficient for nuclear 
export and hence are not functional NESs.
Nuclear export of TDP-43 and FUS is independent of CRM1. Even though the predicted CRM1- 
dependent NESs are non-functional, export of TDP-43 and FUS could still be mediated by CRM1, either via a 
non-canonical NES not identified by the above mentioned NES prediction algorithms, or via a binding part-
ner that contains a CRM1-dependent NES. We therefore tested whether pharmacological inhibition of CRM1 
with leptomycin B (LMB), a well-known CRM1-specific inhibitor47, impairs nuclear export of TDP-43 or FUS 
in the heterokaryon assay. As a positive control for LMB activity, localization of p62/SQSTM1, a known CRM1 
export substrate48, was analyzed in parallel. After LMB treatment for 2 hours, p62 strongly relocalized from the 
cytoplasm to the nucleus (Fig. S3A), demonstrating that LMB at the given concentration efficiently inhibited 
CRM1-dependent protein export in HeLa cells. In contrast, treatment of heterokaryons with LMB did not impair 
shuttling of TDP-43 and FUS from the human to the mouse nucleus (Fig. 2A), demonstrating that nuclear export 
of TDP-43 and FUS occurs independently of CRM1.
To further substantiate this finding, we made use of HeLa cells stably expressing mCherry-tagged TDP-43 
or FUS with a mutated NLS (mNLS), which show a partial cytosolic mislocalization45. We reasoned that if TDP-
43 and FUS would be exported via CRM1, LMB treatment or silencing of CRM1 with siRNA should shift the 
equilibrium towards a more nuclear localization. However, LMB treatment for 2.5 h did not alter the subcellular 
distribution of NLS-mutant TDP-43 or FUS (Fig. 2C). Similarly, 3 days after transfection with CRM1-specific 
siRNA, which efficiently reduced CRM1 protein levels (Fig. 2D,E), NLS-mutant TDP-43 and FUS showed the 
same predominantly cytosolic localization as in control siRNA-treated cells (Fig. 2E). Moreover, combining 
CRM1 knockdown and LMB treatment did not result in a more nuclear accumulation of NLS-mutant TDP-43 
or FUS (Fig. S3B). Taken together, this demonstrates that TDP-43 and FUS are not primarily exported via CRM1 
and hence are capable of utilizing alternative nuclear export routes.
TDP-43 and FUS are exported independently of Exportin-5. As overexpression of the yeast homo-
logue of Exportin-5, MSN5, was shown to enhance TDP-43 toxicity in yeast49, we next tested whether Exportin-5 
(XPO5) is involved in nuclear export of TDP-43 and FUS. To this end, we used siRNA to silence XPO5 in HeLa 
cells stably expressing NLS-mutant TDP-43 and FUS. XPO5 knockdown was efficient, as demonstrated by immu-
noblotting (Fig. S4A) or co-staining with an Exportin-5-specific antibody (Fig. S4B), respectively. Nevertheless, 
NLS-mutant TDP-43 or FUS did not show an altered subcellular localization upon XPO5 silencing (Fig. S4B), 
demonstrating that Exportin-5 is not responsible for transporting TDP-43 and FUS out of the nucleus.
Nuclear export of TDP-43 and FUS does neither require RNA-binding nor the mRNA export 
machinery. As TDP-43 and FUS are RNA-binding proteins involved in pre-mRNA splicing of numerous 
target RNAs4,6, it seems possible that they are exported along with fully spliced mRNAs via the mRNA export 
machinery. To address this hypothesis, we analyzed nuclear export of RNA-binding-deficient TDP-43 and FUS 
mutants (Fig. 3A) in the heterokaryon assay. In TDP-43, the predominant RNA-binding domain is RRM1, and 
deletion of this domain (ΔRRM1) as well as point mutation of key phenylalanines responsible for direct RNA 
interactions of RRM1 (2FL) and RRM1/RRM2 (4FL) were previously shown to abrogate RNA-binding and TDP-
43′s autoregulation and RNA-splicing activity50,51. In FUS, we mutated residues previously shown to be crucial for 
RNA-binding of the RRM domain52,53 and a homologous RanBP2-type zinc finger (mRRM/mZnF)54. In another 
construct, we exchanged all RGG motifs to KGG motifs (mRGG), as RGG mutations were recently shown to 
abrogate high affinity RNA-binding of FUS in cells55. We found that all mutant proteins were still able to shuttle 
from the human to the mouse nucleus of heterokaryons within 2–3 h (Fig. 3B), indicating that mRNA-binding 
is not required for nuclear export of TDP-43 and FUS. To complement this finding, we silenced a key factor of 
the mRNA export machinery, Aly/REF, and examined whether this causes nuclear relocalization of NLS-mutant 
TDP-43 or FUS. Aly/REF is part of the TREX complex that recruits the TAP/p15 export receptor to processed 
mRNPs and allows their interaction with NPCs and passage through nuclear pores56,57. Aly/REF protein levels 
were efficiently reduced 3 days after siRNA transfection (Fig. 3C) and cells with reduced Aly/REF levels showed 
an accumulation of poly(A) + RNA in the nucleus (Fig. 3D), as previously reported58. Nevertheless, localization 
of NLS-mutant TDP-43 or FUS was indistinguishable in Aly/REF-depleted cells and control cells (Fig. 3D). This 
suggests that nuclear export of TDP-43 and FUS does not require a functional mRNA export machinery and 
occurs independently of bulk mRNA export.
Artificial enlargement of TDP-43 and FUS impairs their nuclear egress. As TDP-43 and FUS 
appear to be exported independently of major protein export receptors (CRM1, Exportin-5) and the bulk 
mRNA export machinery, we next tested the hypothesis that the two proteins exit the nucleus by passive diffu-
sion. To test our hypothesis directly, we adapted the hormone-inducible nuclear transport assay from Love et al., 
in which the hormone-binding domain of the glucocorticoid receptor (GCR) is fused to an NLS-containing 
protein-of-interest59. The GCR domain traps the fusion protein in the cytoplasm until addition of a steroid 
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hormone, e.g. dexamethasone (DEX), triggers nuclear import; removal of the steroid hormone induces nuclear 
re-export (Fig. 4A). We fused two GCR domains (65 kDa total) and two EGFPs (54 kDa total) (GCR2-EGFP2) 
to the N-terminus of TDP-43 and FUS and thus enlarged them by 119 kDa, creating fusion proteins of 162 kDa 
and 172 kDa, respectively. If TDP-43 and FUS indeed exit the nucleus by passive diffusion, these large fusion 
proteins should leave the nucleus very slowly, as the rate of passive macromolecular diffusion through NPCs 
strongly decreases with increasing molecular weight60,61. In the absence of dexamethasone, GCR2-EGFP2-TDP-43 
Figure 2. Nuclear export of TDP-43 and FUS is CRM1-independent. (A) Heterokaryon assay performed to 
analyze nuclear export of TDP-43 and FUS with or without CRM1 inhibition. 20 nM Leptomycin B (LMB) 
was added to heterokaryons directly after fusion and cells were incubated for 2 h (TDP-43) and 3 h (FUS), 
respectively, in the presence of cycloheximide. Cells were stained with a V5- or HA-specific antibody (green), 
a human hnRNP-C-specific antibody (magenta) and DAPI as a nucleic acid stain (blue). LMB does not inhibit 
shuttling of TDP-43 and FUS from human to mouse nuclei (marked with an asterisk in the DAPI channel), 
demonstrating that export of TDP-43 and FUS is CRM1-independent. Scale bars: 20 μm. (B) Hela cells stably 
expressing mCherry-tagged TDP-43 and FUS with mutated NLS (mNLS) were treated with LMB (20 nM) for 
2.5 hours. LMB treatment does not cause a nuclear accumulation of NLS mutant proteins. Scale bars: 20 μm. 
(C) and (D) HeLa cells stably expressing mCherry-TDP-43-mNLS or mCherry-FUS-mNLS were transfected 
with control or CRM1-specific siRNA. 3 days post-transfection, CRM1 levels in total cell lysates were analyzed 
by Western blotting, β-actin served as a loading control. (C) In parallel, cells were stained with a CRM1-
specific antibody (green), a mCherry-specific antibody (magenta) and DAPI and were imaged by fluorescence 
microscopy. (D) Cells with reduced CRM1 levels do not show a nuclear accumulation of mCherry-tagged NLS 
mutant TDP-43 or FUS. Scale bars: 20 μm.
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Figure 3. Nuclear export of TDP-43 and FUS does not require RNA-binding and is independent of the mRNA 
export machinery. (A) Schematic diagram of RNA-binding deficient TDP-43 and FUS mutants. 2FL = F147L/
F149L; 4FL = F147L/F149L/F229L/F231L; mRRM/mZnF = 7 point mutations in the RRM domain/6 point 
mutations in the zinc finger (see methods for details); mRGG = all Rs in RGG motifs were exchanged for K. 
(B) The indicated flag-tagged TDP-43 or EGFP-FUS constructs were transiently transfected into HeLa cells 
and nuclear export was examined in the interspecies heterokaryon assay. Heterokaryons were incubated for 
2 h (TDP-43) and 3 h (FUS), respectively, in the presence of cycloheximide and localization of TDP-43 or FUS 
proteins were visualized by flag immunostaining or direct EGFP fluorescence (green), respectively, hnRNP-C 
immunostaining (magenta) and DAPI (blue). Both wild-type (WT) and RNA-binding deficient mutant versions 
of TDP-43 and FUS shuttle from human to mouse nuclei (marked with an asterisk in the DAPI channel). Scale 
bars: 20 μm. (C) and (D) HeLa cells stably expressing mCherry-TDP-43-mNLS or mCherry-FUS-mNLS were 
transfected with control or Aly/REF-specific siRNA. 3 days post-transfection, Aly/REF levels in total cell lysates 
were analyzed by Western blotting, β-actin served as a loading control (C). In parallel, cells were processed for 
fluorescence in situ hybridization (FISH) and immunocytochemistry to visualize poly(A) + mRNA (white), 
Aly/REF (green), mCherry-TDP-43/FUS-mNLS (magenta) and were stained with DAPI (blue) (D). Cells 
with reduced Aly/REF levels show a nuclear accumulation of poly(A) + mRNA (arrows), however no nuclear 
accumulation of mCherry-tagged NLS mutant TDP-43 or FUS. Scale bars: 20 μm.
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Figure 4. TDP-43 and FUS enlarged by ~120 kDa are poorly exported, suggesting that TDP-43 and FUS leave 
the nucleus by passive diffusion. (A) Schematic diagram of the hormone-induced nuclear transport assay. An 
NLS-containing protein-of-interest (X) is attached to the hormone-responsive domain of the glucocorticoid 
receptor (GCR). The GCR domains trap the fusion protein in the cytoplasm until dexamethasone addition 
(+DEX) releases trapping and induces rapid nuclear import. If the protein-of-interest contains an NES that 
mediates active nuclear export, rapid relocalization to the cytoplasm is observed after dexamethasone washout. 
(B) GCR2-EGFP2 (119 kDa) fused to TDP-43 or FUS were transiently expressed in HeLa cells and nuclear 
import was induced by DEX addition (+DEX). Localization of fusion proteins was examined at the indicated 
timepoints after DEX washout in the absence or presence of leptomycin B (LMB). Even 5 h after DEX removal, 
GCR2-EGFP2-TDP-43 or -FUS remain predominantly nuclear and only small amounts are observed in the 
cytoplasm. In contrast, GCR-EGFP-Rev (73 kDa), which contains a functional CRM1-dependent NES, is 
efficiently exported after DEX washout and its export is blocked by LMB treatment, demonstrating CRM1 
dependence. Scale bars: 20 μm. Bar graphs to the right show MFI Cyt/Nuc ratios for the 0 h and 5 h timepoints 
(40 cells/condition from one representative experiment out of three), error bars indicate SD.
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and -FUS were largely cytosolic, but rapidly translocated into the nucleus upon dexamethasone addition 
(Fig. 4B). After washout of dexamethasone, they remained largely nuclear over the course of 5 hours, whereas 
the well-characterized CRM1 cargo Rev62,63 fused to GCR-EGFP showed efficient re-export during the same time 
period (Fig. 4B, lower panels). Cytosolic relocalization of the GCR-EGFP-Rev fusion protein (73 kDa) occurred 
primarily by active CRM1-mediated nuclear export and not by passive diffusion, as it was blocked by LMB 
(Fig. 4B), thus serving as an appropriate positive control for receptor-mediated active export. These data suggest 
that nuclear export of TDP-43 and FUS becomes highly inefficient when the proteins are enlarged. This behavior 
is typically observed for cargoes that permeate NPCs by passive diffusion64. Thus, at least in HeLa cells, TDP-43 
and FUS appear to egress from the nucleus primarily by passive diffusion rather than active, receptor-mediated 
export.
To further substantiate this conclusion, we utilized the NEX-TRAP (Nuclear Export Trapped by RAPamycin) 
nuclear export assay, which is based on rapamycin-induced dimerization of FRB (FK506-rapamycin (FR)-binding 
domain) and FKBP (FK506-binding protein-12)65 (see Fig. 5A for a schematic diagram). 3 FKBP domains are 
exposed on the cytoplasmic side of the trans Golgi network (TGN) by fusion to an integral membrane pro-
tein (gM-FKBP3) and serve as a cytoplasmic reporter (Fig. 5A). The potential nuclear export cargo is fused to 
FRB, EYFP (for direct visualization) and three SV40 NLSs (for efficient nuclear import). Without rapamycin, 
EYFP-NLS-FRB fusion proteins with export activity continuously shuttle between the nucleus and cytoplasm, 
whereas addition of rapamycin induces dimerization of FRB and FKBP and traps the shuttling protein at the 
TGN. If the fusion protein does not contain an NES that mediates active nuclear export, trapping at the TGN 
does not occur. We fused EYFP-NLS-FRB (43 kDa) to the N-terminus of TDP-43 or FUS (Fig. 5B) and tested 
whether rapamycin induces trapping of the fusion proteins on the gM-FKBP3 reporter. However, both in the 
absence and presence of rapamycin (for 2 h), the TDP-43 and FUS fusion proteins were localized in the nucleus 
and no relocalization and trapping in the cytoplasm by TGN-resident gM-FKBP3 was observed (Fig. 5C, upper 
and middle panels). In contrast, our positive control, the NES-containing HSV-1 protein UL465,66 (21 kDa) fused 
to EYFP-NLS-FRB was readily depleted from the nucleus and co-localized with gM-FKBP3 at the TGN upon 
rapamycin addition (Fig. 5C, lower panels). Although we cannot exclude that the SV40 NLSs present in the 
EYFP-NLS-FRB tag is simply too strong and masks export of the TDP-43 and FUS fusion proteins by causing 
immediate re-import, the results from the NEX-TRAP assay support the idea that TDP-43 and FUS lack an effi-
cient NES that mediates active nuclear export.
Together, our results imply that TDP-43 and FUS, at least in HeLa cells, leave the nucleus predominantly by 
passive diffusion, as artificial enlargement of both proteins strongly impaired their nuclear egress, which is com-
patible with recent models of passive diffusion through NPCs60,61,67.
Newly synthesized RNA retains TDP-43 in the nucleus and limits its diffusion into the cytoplasm. 
As TDP-43 and FUS appear to leave the nucleus by passive diffusion, intranuclear interactions could limit or 
slow down nuclear egress of TDP-43 and FUS by nuclear retention. TDP-43 and FUS are known to bind to 
long introns of hundreds or thousands of pre-mRNAs and to regulate alternative splicing3,5,6,68. We therefore 
speculated that newly synthesized RNA could act as an anchor that retains TDP-43 and FUS in the nucleus and 
limits their diffusion through NPCs into the cytoplasm. To test this hypothesis, we treated HeLa cells with the 
transcriptional inhibitor actinomycin D (Act D) for 3 hours and examined subcellular localization and biochem-
ical extractability of TDP-43 and FUS in comparison to untreated cells. Indeed, Act D treatment caused a slight 
cytosolic relocalization of TDP-43 (Figs 6A, S5B), consistent with a previous report69. Cytoplasmic relocalization 
of TDP-43 was not observed with stress treatments that induce stress granules, e.g. arsenite treatment or heat 
shock, and no G3BP1-positive stress granules were observed in Act D-treated cells (Fig. 6A), demonstrating 
that cytoplasmic relocalization of TDP-43 upon Act D treatment is not due to stress granule formation. FUS 
remained predominantly nuclear after Act D treatment (Fig. S5A,B), however, cytoplasmic redistribution of FUS 
has previously been reported to occur under transcriptional inhibition70. Hence, it is possible that the anti-FUS 
antibody we used was not sensitive enough to detect small amounts of FUS in the cytoplasm, or that cytoplasmic 
FUS is very rapidly re-imported by its nuclear import receptor Transportin21,71. Upon hypotonic lysis and nuclear/
cytoplasmic fractionation, TDP-43 was mostly restricted to the nuclear fraction in untreated, arsenite-treated 
and heat-shocked cells, but could be partially extracted from nuclei of Act D-treated cells (Fig. 6B). This suggests 
that newly synthesized RNA retains TDP-43 in the nucleus, whereas transcriptional inhibition causes TDP-43 
to become soluble and extractable into the cytoplasmic fraction. A higher extractability from the nucleus was 
also observed for a mutant version of TDP-43 that is unable to bind to RNA (EGFP-TDP-4FL)50 (Fig. S5C). 
Nevertheless, EGFP-TDP-4FL was exclusively found in the nucleus, possibly because the previously described oli-
gomerization/partitioning of the mutant protein into nuclear granules69 (Fig. S5D) precludes its diffusion across 
NPCs into the cytoplasm.
To examine whether transcriptional inhibition indeed accelerates nuclear egress of TDP-43 in intact and living 
cells, we treated EGFP-TDP-43-expressing HeLa cells with or without Act D for 3 hours and measured the loss of 
nuclear EGFP fluoresence upon repeated bleaching of defined areas in the cytoplasm (fluorescence loss in pho-
tobleaching, FLIP, see schematic diagram in Fig. 6C). In this assay, loss of nuclear EGFP fluorescence is primarily 
a measure of the nuclear export rate. While a minor contribution of re-import into the nucleus cannot entirely 
be excluded, it should be insignificant in this assay, as the cytoplasmic pool of EGFP-TDP-43 is very small and 
the entire cytoplasm is eventually bleached by repeated photobleaching of defined cytoplasmic areas72. Indeed, 
we observed a more rapid loss in nuclear EGFP fluorescence in Act D-treated cells compared to untreated cells 
(Fig. 6D,E), indicating that EGFP-TDP-43 leaves the nucleus more rapidly upon transcriptional inhibition. To 
exclude that loss of nuclear EGFP fluorescence was caused unspecifically by Act D treatment, e.g. due to reduced 
cell viability, we performed FLIP analysis in cells expressing EGFP-tagged histone H3.3. For this control protein, 
only a slight loss of nuclear EGFP fluorescence was observed in Act D-treated cells over the same time course 
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Figure 5. TDP‐43 and FUS are not actively exported in the NEX‐TRAP nuclear export assay. (A) Schematic 
diagram of the NEX-TRAP nuclear export assay. (B) Schematic diagram of fusion proteins used in the 
NEX-TRAP assay. (C) HeLa cells were co-transfected with a gM-FKBP3 construct and constructs encoding 
either pEYFP-NLS-FRB-TDP-43 or pEYFP-NLS-FRB-FUS. As a positive control, a plasmid encoding EYFP-
NLS-FRB-pUL4 (a known CRM1 cargo) was used. 20 h post-transfection, cells were treated with the protein 
synthesis inhibitor anisomycin for 10 min and incubated for another 2 h in the presence or absence of rapamycin 
(RAP). Protein localization was visualized by anti-gM immunostaining (red); EYFP-tagged proteins were 
visualized directly (green); nuclei were visualized by DAPI staining (blue) and are marked by dashed lines. Scale 
bars: 10 μm.
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Figure 6. Inhibition of RNA synthesis causes accelerated nuclear egress of TDP-43. (A) HeLa cells were either 
left untreated or treated with Actinomycin D (Act D, 5 µg/ml for 3 h), arsenite (0.5 mM for 30 min) or heat shock 
(44 °C for 1 h) and localization of TDP-43 and stress granule formation were examined after immunostaining 
with antibodies specific for TDP-43 (white), the stress granule marker G3BP1 (green) and DAPI staining (blue). 
Act D treatment causes a slight relocalization of TDP-43 to the cytoplasm in the absence of stress granule 
formation. Other stress treatments induce stress granules without inducing TDP-43 relocalization. Scale bar: 
20 µm. (B) HeLa cells treated as indicated in A were subjected to hypotonic lysis and separated into a nuclear 
fraction (N) containing insoluble nuclear proteins and a cytoplasmic fraction (C) containing soluble nuclear 
and cytoplasmic proteins. Fractions were analyzed by SDS-PAGE and immunoblotting with TDP-43- or FUS-
specific antibodies. GAPDH served as a cytosolic marker, Histone H3 as a nuclear marker protein. While TDP-
43 is predominantly in the nuclear fraction of untreated, arsenite-treated and heat shocked cells, it is extracted 
from nuclei into the cytoplasmic fraction after Act D treatment. FUS remains predominantly in the nuclear 
fraction upon inhibitor treatment. Bar graph shows a quantification of TDP-43 immunoblot signals. Mean grey 
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(Fig. S6A,B). Thus, the much stronger loss of nuclear EGFP fluorescence observed for EGFP-TDP-43 most likely 
predominantly results from accelerated nuclear egress of TDP-43 upon transcriptional inhibition.
Discussion
In our study we examined how TDP-43 and FUS leave the nucleus, as the nuclear export routes of the two shut-
tling hnRNPs have not been characterized so far. In particular, we sought to test the hypotheses that TDP-43 
and FUS are exported by the nuclear export receptor CRM1 and that inhibition of CRM1 may be a therapeutic 
strategy to compensate for defective nuclear import of TDP-43 and FUS. Our results clearly demonstrate that 
TDP-43 and FUS leave the nucleus independently of CRM1 and that pharmacologic inhibition of CRM1 is una-
ble to restore nuclear localization of TDP-43 and FUS when their nuclear import is impaired. Our findings are in 
line with quantitative proteomic studies that searched for proteins that bind to CRM1 in a Ran-GTP-dependent 
manner73 or shift their localization upon LMB treatment74,75. In these studies, TDP-43 and FUS were not among 
the CRM1-binding proteins or proteins that show elevated nuclear levels upon CRM1 inhibition. Our data sug-
gest that CRM1 inhibitors (e.g. KPT-350) most likely exert their promising neuroprotective effects33,36,37 inde-
pendently of TDP-43 and FUS. Instead, their beneficial effects must be due to inhibiting export of other CRM1 
cargoes, e.g. Tau and NRF2 (nuclear factor, erythroid 2 like 2). Deciphering the neuroprotective mechanism of 
CRM1 inhibitors in different models of neurodegeneration will be an interesting task for the future.
We also tested whether previously predicted leucine-rich NESs in TDP-43 (NES-239 IAQSLCGEDLII)30 and 
FUS (NES-289 VQGLGENVTI)23 have NES activity using the heterokaryon nuclear export assay. We found 
that TDP-43 and FUS are able to leave the nucleus even when key hydrophobic residues in the predicted NES 
are exchanged for alanine. We cannot completely exclude that other functional CRM1-dependent NESs, not 
predicted by available NES prediction tools, are present in TDP-43 and FUS. However, we consider this highly 
unlikely, as we found that neither pharmacological CRM1 inhibition nor siRNA-mediated CRM1 silencing (or 
both combined) alter nuclear egress/localization of TDP-43 or FUS. For TDP-43, it was furthermore shown that 
TDP-43 localization is unaffected by CRM1 inhibition in primary rat neurons76, suggesting that our findings, at 
least for TDP-43, are not limited to cell lines, such as HeLa cells, but can be extended to neuronal cells.
In light of our finding, the question arises what causes nuclear aggregation of TDP-43 when the predicted NES-
239 is mutated30, and why toxicity associated with TDP-43 or FUS overexpression is suppressed when the predicted 
NES is deleted43,77,78. Both predicted signals are located in RNA recognition motif (RRM) domains, hence it seems 
possible that the point mutations/deletion alter RRM folding and impair RNA-binding of TDP-43 or FUS. Loss of 
RNA-binding is expected to cause nuclear aggregation of TDP-4369,79 and to reduce TDP-43- or FUS-associated tox-
icity52,80,81. In direct support of the idea that mutations in the predicted “NES-239” of TDP-43 abrogate RNA-binding, 
this sequence was shown to be located within the hydrophobic core of the TDP-43 RRM2 domain82 and mutations 
in “NES-239” were found to disrupt TDP-43’s splicing activity76. In summary, we conclude that the previously pre-
dicted and commonly annotated NESs in TDP-43 and FUS are not functional. Mutations in these motifs do not 
affect nuclear egress of TDP-43 and FUS and hence are not suited to experimentally trap TDP-43 or FUS in the 
nucleus. Instead, they most likely impair RNA-binding and RNA processing functions of TDP-43 and FUS, which 
should be kept in mind when interpreting data generated with such “NES” mutant versions.
Besides addressing CRM1 as possible export receptor, we excluded that Exportin-5 or the mRNA export 
machinery solely mediate nuclear export of TDP-43 and FUS. We considered Exportin-5 as a possible candidate, 
as it has been genetically linked to TDP-43 toxicity49. Export along with mRNA appeared to be a likely scenario, as 
TDP-43 and FUS are well-known RNA binding proteins and FUS was found to be associated with CIP29, a com-
ponent of the TREX mRNA export complex83. Overall, our data argue against a predominantly receptor-mediated 
nuclear export of TDP-43 and FUS, as artificial enlargement (with domains of 43 or 119 kDa, respectively) inter-
fered with nuclear egress of both proteins. These data support the idea that TDP-43 and FUS leave the nucleus to a 
large extent by passive diffusion. It is well known that passive macromolecular diffusion through NPCs decreases 
strongly as macromolecules increase in size. Older studies reported a size threshold of 40–60 kDa84–86. However, 
more recent studies indicate that there is no firm size threshold, but rather a soft barrier to passive diffusion that 
gradually intensifies with increasing size of macromolecules61,67. Consistent with this model, smaller molecules 
passively permeate NPCs within minutes, whereas larger molecules (of up to 230 kDa) were found to permeate 
NPCs on the time scale of hours60,61,64. Nuclear egress of TDP-43 and FUS appears to follow this model of passive 
diffusion: Both proteins shuttle efficiently between nuclei of heterokaryon when they carry a small epitope tag 
(V5-TDP-43 or HA-FUS), but poorly exit the nucleus when tagged with larger domains (>43 kDa). This sug-
gests that TDP-43 and FUS, at least in HeLa cells, leave the nucleus by passive diffusion rather than facilitated 
receptor-mediated export.
value (MGV) of bands in cytoplasmic/nuclear fraction of three independent experiments are shown, error bars 
represent SEM; *p-value ≤ 0.05 by one-way Anova with Dunnett’s multiple comparison test. (C) Schematic 
diagram of FLIP assay used to measure nuclear export of EGFP-TDP-43 in living HeLa cells. Three defined areas 
in the cytoplasm are repeatedly bleached, while fluorescence loss of the EGFP-signal in the nucleus is monitored 
over time using spinning disc confocal miscroscopy. (D) Representative images of untreated and 3 h Act 
D-treated EGFP-TDP-43-expressing cells recorded during FLIP analysis. Act D-treatment leads to accelerated 
loss of the nuclear EGFP-signal, whereas the nuclear EGFP-signal remains constant in untreated cells over the 
course of ~30 min. Scale bars: 10 μm. (E) Rate of nuclear egress of EGFP-TDP-43 measured by FLIP analysis in 
untreated and 3 h Act D-treated HeLa cells. Relative fluorescence intensity of the nuclear EGFP-signal is stable 
in untreated cells, but decreases over time in Act D-treated cells, demonstrating that transcriptional inhibition 
accelerates nuclear egress of TDP-43101.
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The notion that TDP-43 and FUS leave the nucleus by passive diffusion implies that any molecular interac-
tions that (i) lead to higher molecular weight complexes of TDP-43 or FUS or (ii) trap TDP-43 or FUS on nuclear 
structures will reduce their nuclear egress and favor a predominantly nuclear localization. In the case of TDP-
43, it has been recently reported that TDP-43 forms homo-oligomers (dimers, tetramers and higher oligomeric 
species) under physiological conditions, which antagonizes its pathological aggregation87. FUS also has been 
suggested to self-assemble and oligomerize on chromatin-associated RNAs88,89. Our data imply that physiological 
oligomerization of TDP-43 and FUS could limit their nuclear egress, as large oligomeric TDP-43 or FUS species 
are expected to poorly permeate NPCs by passive diffusion. To test this hypothesis, it will be interesting to exam-
ine whether oligomerization-deficient mutants leave the nucleus at an enhanced rate, and whether enhanced 
nuclear egress contributes to the reported reduction in splicing activity and enhanced cytoplasmic aggregation 
of oligomerization-deficient TDP-4387. If so, this would underscore the proposal that stabilizing physiological 
TDP-43 or FUS oligomers could be an attractive therapeutic strategy to counteract cytoplasmic mislocalization 
and aggregation of the two proteins.
For TDP-43, we furthermore found that newly synthesized RNA could retain the protein in the nucleus and 
limit its egress into the cytoplasm, as inhibition of transcription causes accelerated loss of TDP-43 from the 
nucleus. Loss of this nuclear retention mechanism could be one factor that contributes to TDP-43 mislocaliza-
tion and disease progression in ALS/FTD, possibly as a consequence of the widespread RNA processing changes 
that occur in both diseases3. Interestingly, a few ALS-associated mutations in TDP-43 are located in the RRM1 
domain (P112H90 and D169G91) or directly adjacent to the RRM2 domain (K263E92 and K267S)93. Moreover, 
stress-induced acetylation of lysine residues in RRM1 and RRM2 of TDP-43, as found in ALS spinal cord, was 
shown to impair RNA-binding94. If mutations or acetylation cause a mild RNA-binding defect (not as severe as 
for the F4L mutant) and thus the mutant or acetylated protein remains soluble (not oligomerized/granular as the 
F4L mutant), their nuclear egress might be facilitated due to reduced retention on nuclear RNA. This speculative 
model would be in line with a model proposed by Ling et al., which posits that de-regulated gene expression and 
disrupted protein homeostasis are intimately linked3. Perturbation of RNA homeostasis may cause a vicious circle 
that leads to further protein and RNA homeostasis defects and drives disease progression. Loss of nuclear reten-
tion of TDP-43 on newly transcribed pre-mRNAs may be part of this detrimental cycle that eventually disturbs 
proper TDP-43 localization and function.
Material and Methods
Antibodies. Secondary antibodies. For immunocytochemistry the following antibodies were used: Alexa 
Fluor® 488 Donkey anti-Goat, Alexa Fluor® 488 Donkey anti-Mouse, Alexa Fluor® 488 Donkey anti-Rabbit, 
Alexa Fluor® 488 Donkey anti-Rat, Alexa Fluor® 555 Donkey anti-Mouse, Alexa Fluor® 555 Donkey anti-Rabbit, 
Alexa Fluor® 555 Donkey anti-Rat, Alexa Fluor® 647 Donkey anti-Mouse, Alexa Fluor® 647 Donkey anti-Rabbit 
(Invitrogen).
For immunoblotting, the following antibodies were used: IRDye® 680RD Donkey anti-Mouse IgG, IRDye® 
680RD Goat anti-Rat IgG, IRDye® 800CW Donkey anti-Rabbit IgG (LI-COR). For visualization of the the 
Dig(T)40 probe, FITC-labeled anti-Digoxigenin-AP, Fab fragments from sheep (Roche) was used.
Cloning and cDNA constructs. TDP-43 and FUS carrying mutations in putative nuclear export signals (NES) 
(mNES/double-mNES) were generated by QuikChange mutagenesis (Stratagene) using pcDNA6-TDP-43-V595 
and pcDNA3.1-hygro(−)-HA-FUS21 as templates. TDP-43 mNES-222 and FUS mNES-289 were used as tem-
plates to generate double-mNES mutants. TDP-43 and FUS constructs carrying mutations in the NLS (mNLS, 
for TDP-43: amino acids 83–85 exchanged for alanine; for FUS: P525L mutation) as well as in the putative NESs 
(mNLS/double-mNES) were generated by QuikChange mutagenesis (Stratagene). Constructs encoding EGFP 
fused to putative NES sequences were cloned by oligonucleotide annealing and HindIII/BamHI restriction 
digest into the pEGFP-C1 (Clontech) mammalian expression vector. To generate GCR2-EGFP2-TDP-43 and 
GCR2-EGFP2-FUS constructs, TDP-43 and FUS cDNAs were cloned by enzyme restriction digest into the modi-
fied pEGFP-C1 vector containing a GCR2-EGFP2 cassette96. FUS mRRM/mZnF (F305L/K312A/K315A/K316A/
F341L/F359L/F368L/D425A/N435A/F438A/W440A/R441A/N445A) and mRGG cDNAs were commercially 
synthesized (Genscript) and cloned by enzyme restriction digest into the pEGFP-C2 (Clontech) mammalian 
expression vector. Constructs encoding flag-TDP-43 and RNA-binding-deficient mutants thereof were kindly 
provided by Emanuele Buratti and Francisco Baralle51,69. EGFP-TDP-43 (F4L) construct was generated by sub-
cloning TDP-43-4FL into the pEGFP-C3 (Clontech) mammalian expression vector. Lentiviral constructs used 
for generation of stable HeLa cell lines were in pCDH-Ef1-MCS-IRES-Puro (System Biosciences). Construct 
encoding EGFP-histone H3.3 was kindly provided by Sandra Hake97. The integrity of all constructs was verified 
by sequencing. Oligonucleotide sequences are available upon request.
Stable HeLa cell lines. HeLa cells stably expressing HA-FUS were described in98. HeLa cells stably expressing 
TDP-43-V5, mCherry-TDP-43-dNLS and mCherry-FUS-P525L were generated by lentiviral transduction as 
described in99, followed by selection with puromycin (0.5 µg/ml, Sigma). Single cell clones of mCherry-TDP-
43-dNLS and mCherry-FUS-P525L-expressing lines were obtained by fluorescence activated cell sorting (FACS) 
and expansion of mCherry + single cell clones.
Cell culture, transfection and drug/stress treatments. HeLa cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with Glutamax (Life Technologies) supplemented with 10% (vol/vol) fetal calf serum (FCS, 
Life Technologies) and Gentamycin (10 µg/mL, Invitrogen). For the hormone-induced nuclear export assay, HeLa 
cells were cultured in DMEM supplemented with 10% (vol/vol) dialyzed fetal bovine serum (FBS, ThermoFisher). 
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Transfections were carried out with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruc-
tions. Were indicated, leptomycin B (20 nM, Santa Cruz Biotechnology) was added to the culture medium for 
the indicated time. Actinomycin D (5 µg/mL, Sigma) treatment was carried out for 3 hours and sodium arsenite 
(0.5 mM, Sigma) treatment for 30 min. Heat shock was performed by incubating cells for 1 hour in a tissue culture 
incubator heated to 44 °C. To induce nuclear import of GCR2-GFP2-fusion proteins, cells were incubated for 
20 min with dexamethasone (5 µM, Sigma).
Interspecies heterokaryon assay. HeLa cells were seeded onto coverslips in a 12-well-plate and transfected with 
the indicated constructs. After 5 h, medium was removed and mouse embryonic fibroblasts (MEFs) were added. 
24 h post-transfection, HeLa cells were fused with MEFs by a 2 min incubation with polyethylene glycol (PEG 
1500, Roche) at room temperature. PEG was removed by washing 3 times in PBS supplemented with Glucose 
(0.1%, Merck). Post-fusion, cells were incubated in antibiotic-free DMEM in the presence of cycloheximide 
(75 µg/mL, ROTH) to inhibit protein synthesis and further processed by immunocytochemistry.
siRNA-mediated knockdown. Knockdown of Aly/REF, CRM1 and XPO5 was achieved using Dharmacon siGE-
NOME SMARTpools composed of 4 different siRNAs. siRNA transfections were carried out with Lipofectamine 
2000 at a final concentration of 25 nM siRNA. Culture medium was exchanged 5 h post-transfection and the 
knockdown was analyzed 72 h post-transfection by immunoblotting and immunocytochemistry.
NEX‐TRAP assay. The NEX-TRAP assay was performed as described65. Briefly, HeLa cells were co-transfected 
for 20 hours with the plasmid pCR3-N-HA-UL10/gM-FKBP3 and either pEYFP-NLS-FRB-TDP-43 or 
pEYFP-NLS-FRB-FUS. As control, a plasmid encoding EYFP-NLS-FRB-pUL4 was used65. Following 10 min 
anisomycin (50 µM) treatment, cells were incubated for 2 h with rapamycin (150 ng/ml, + RAP) or without 
rapamycin (−RAP) in the presence of anisomycin. Subsequently, gM was visualized by immunocytochemistry, 
EYFP-tagged proteins were visualized directly and nuclei were visualized by DAPI staining.
Poly(A)+RNA in situ hybridization. All reagents were treated with 0.1% diethyl pyrocarbonate (DEPC, Sigma). 
Cells grown on 12 mm coverslips were fixed for 15 min at room temperature in 4% formaldehyde in PBS, permea-
bilized on ice for 5 min in 0.5% Triton X-100 in PBS and equilibrated on ice for 5 min with 2× SSC (Ambion) and 
25% formamide in PBS. Cells were hybridized for 2 h at 37 °C with 1 ng/ml digoxygenin labeled oligo(dT) (40mer, 
Eurofins) in 2× SSC, 1 mg/ml tRNA, 0.02% bovine serum albumin (BSA), 2 mM ribonucleoside vanadyl com-
plex (RVC, Sigma), 25% formamide, 5% dextrane sulfate. Afterwards, cells were washed 2× with 2× SSC/25% 
formamide in PBS, followed by a washing step with 0.5× SSC in PBS and once with 0.2% Triton X-100 in PBS. 
Subsequently, immunocytochemistry was carried out using a FITC-coupled anti digoxygenin Fab fragment 
(1:300, Roche) for detection of the labeled oligonucleotide and specific antibodies for the indicated proteins, 
respectively.
Immunocytochemistry. All steps were carried out at room temperature. Cells were fixed for 10 min in 4% formal-
dehyde in PBS, permeabilized for 5 min in 0.2% Triton X-100 supplemented with 50 mM NH4Cl and blocked for 
30 min with 0.1% saponine in PBS supplemented with 5% goat or donkey serum. Primary antibodies (see Table 1) 
and secondary antibodies were diluted in 0.1% saponine in PBS and were applied for 45 min each and washed 
with 0.1% saponine in PBS. Coverslips were mounted onto glass slides using ProLong Gold Antifade Reagent with 
DAPI (Invitrogen) and dried at room temperature overnight.
Image acquisition and quantification. Images were acquired with an inverted Zeiss Axio Observer.Z1 wide-field 
fluorescence microscope with a 63/1.4NA oil immersion lens and an AxioCam506 and analyzed with Zen soft-
ware (Zeiss). If necessary for better print quality, images were processed by linear enhancement of brightness 
and contrast. Images presenting the NEX-TRAP results were taken using a confocal laser scanning microscope 
(LSM710, Zeiss) and processed using Adobe Photoshop CS3 by linear enhancement of brightness and contrast.
For quantification of mean fluorescence intensity (MFI) in the nucleus and cytoplasm, images were imported 
in the public-domain software Fiji100. In ImageJ, ROIs corresponding to nuclei were identified by DAPI staining 
using the wand tool and MFI in the EGFP channel in nuclear ROI was determined. A band around the nucleus 
(band size = 2 µm) was set as ROI corresponding to the cytoplasm and MFI of the EGFP signal in the cytoplasmic 
ROI was measured. For each construct, 40 cells from one representative experiment were analyzed.
Preparation of RIPA lysates. HeLa cells were harvested in trypsin/EDTA (Sigma) and washed twice with ice-cold 
PBS. Cells were lysed in ice-cold RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate) supplemented with complete protease inhibitor cocktail (Roche). 
Lysates were sonicated and and protein concentrations were determined by BCA protein assay (Pierce).
Nuclear/cytoplasmic fractionation and nuclear extraction. HeLa cells were harvested in trypsin/EDTA (Sigma) 
and washed twice with ice-cold PBS. Cells were incubated in mild cell lysis buffer (20 mM Tris, pH 7.4, 10 mM 
KCl, 3 mM MgCl2, 0.1% NP-40, 10% Glycerol and complete protease inhibitor cocktail (Roche)) for 10 min on 
ice and centrifuged (2000 g) for 10 min at 4 °C to pellet nuclei. Nuclear proteins that are insoluble in mild cell lysis 
buffer remain in the pellet fraction (nuclear fraction, N), whereas soluble nuclear proteins are extracted into the 
supernatant (cytoplasmic fraction, C). 4× SDS-PAGE buffer was added to the cytoplasmic fraction, the nuclear 
fraction was resuspended in the same volume of mild cell lysis buffer and 4× SDS-PAGE buffer was added. Equal 
volumes of cytoplasmic and nuclear fractions were analyzed by SDS-PAGE and immunoblotting with the indi-
cated antibodies.
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SDS-PAGE and immunoblotting. 4× SDS-PAGE buffer was added to samples and samples were boiled for 5 min 
at 95 °C. Proteins were separated by SDS-PAGE gel and transferred to a nitrocellulose membrane (Amersham™ 
Protran™ 0.2 µm NC, GE Healthcare Life Sciences). The membrane was blocked in blocking buffer (Tris-buffered 
saline supplemented with 0.1% Tween-20 (TBS-T) and 5% milk powder) and incubated with the indicated pri-
mary antibodies (see Table 1) and secondary antibodies diluted in blocking buffer, followed by 3 washes in 
TBS-T. Bound antibodies were visualized using the LI-COR fluorescent immunoblotting system (Odyssey CLx 
Imaging system).
Western blot quantification and stastitical analysis. Immunoblots from three independent cell fractionation 
experiments were analyzed. Mean grey values (MGV) in regions-of-interest (ROI) bordering the protein bands 
were measured by Fiji/ImageJ software. MGVs were calculated and converted into cytoplasmic to nuclear ratios 
(c/n). Means of the three independent experiments were calculated and standard error of the mean indicated by 
error bars. The one-way ANOVA with Dunnett’s multiple comparison test (Fig. 6B) as well as the t-test for paired 
samples (Fig. S5C) were used for statistical analysis.
Fluorescent Loss In Photobleaching (FLIP) analysis. HeLa cells were cultured in µ-Dish 35 mm, high Glass Bottom 
(ibidi) and transiently transfected with EGFP-TDP-43or EGFP-histone H3.3 as a control. 24 h post-transfection 
cells were either left untreated or were treated with actinomycin D (5 µg/ml) for 3 hours. Images were acquired 
with an inverted Zeiss Axio Observer.Z1 microscope with a 63/1.4NA oil immersion lens equipped with a confo-
cal spinning disc (CSU-X1, Japan) and a Rapp OptoElectronic laser scanning device (UGA-42, Germany). Before 
bleaching, 5 images were taken in streaming mode with a 488 nm 50 mW SD laser; the same setting were used to 
acquire an image after bleaching. For bleaching, 3 circular ROIs of 6 µm each were repeatedly photobleached in 
the cytoplasm using a 473 nm diode laser (DL-473/75, Rapp OptoElectronic) with full laser power with an iter-
ation of 100 and duration of 200 ms per bleach event. An image was acquired before and after each bleach event 
with 15 s intervals between each bleach event.
The fluorescence loss of a defined area in the nucleus of the bleached cell was measured over time, and cor-
rected for bleaching by acquisition and background noise as follows using the Fiji/ImageJ macro “TimeSeries 
Analyzer”:
= − − .I(t) [ROI1(t) ROI3(t)]/[ROI2(t) ROI3(t)]
ROI1 is defined as the average grey value of an area in the nucleus of the cells which cytoplasm was repeatedly 
photobleached. A corresponding area of a non-photobleached cell in the same field of view served as control for 
bleaching due to image acquisition and is represented by the average grey value of ROI2. ROI3 is the defined 
average grey value of the background. Furthermore, average grey values were normalized to the mean grey value 
of the 5 pre-bleach images (set to 1).
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